A new technology allows scientists to map the DNA-binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by Weill Cornell Medicine and the New York Genome Center.
A clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.
Cornell Prime dots – known as C’ dots – are effective against prostate tumors, according to a new preclinical study led by investigators at Weill Cornell Medicine and the Cornell Duffield College of Engineering.
Schwartz Research Fund Visionary Grants for faculty members in the life sciences aims to provide significant assistance for innovative, visionary research that opens an important new line of inquiry.
Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain most of their weight loss, a clinical trial involving Weill Cornell Medicine has found.
Microbes that cause an infection remain biochemically active after they die, continuing to trigger a host’s immune system while also making the immune response less effective.
Targeting tumor-specific inflammatory processes in colorectal cancer could enhance the efficacy of some anticancer therapies and prevent drug resistance, Weill Cornell researchers have found.